CSIMarket
 
Revance Therapeutics Inc   (NASDAQ: RVNC)
 

Revance Therapeutics Inc's Customers Performance

RVNC



 
RVNC's Source of Revenues During the corresponding time, Revance Therapeutics Inc recorded a revenue increase by 5.47 % year on year, sequentially revenue fell by -8.43 %. While revenue at the Revance Therapeutics Inc 's corporate clients

• List of RVNC Customers




for the same period Revance Therapeutics Inc recorded revenue increase by 5.47 % year on year, sequentially revenue fell by -8.43 %.

• List of RVNC Customers

Revance Therapeutics Inc's Business Units
Product revenue net    98.24 % of total Revenue
RHA Collection of dermal fillers    50.94 % of total Revenue
DAXXIFY    47.3 % of total Revenue






Revance Therapeutics Inc's Comment on Sales, Marketing and Customers
















RVNC's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Revance Therapeutics Inc 380.38 247.00 -1.63 534
SUBTOTAL 0.00 0.00 0.00 -

Sources: Revance Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Revance Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Revance Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.